BioMarin Pharmaceuticals BMRN Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's total liabilities & equity?
- BioMarin Pharmaceuticals (BMRN) reported total liabilities & equity of $8.59B in Q1 2026.
- How has BioMarin Pharmaceuticals's total liabilities & equity changed year-over-year?
- BioMarin Pharmaceuticals's total liabilities & equity increased by 20.2% year-over-year, from $7.15B to $8.59B.
- What is the long-term trend for BioMarin Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's total liabilities & equity has grown at a 5.4% compound annual growth rate (CAGR), from $5.85B to $7.59B.
- What does total liabilities & equity mean?
- The total amount of capital used to fund the company's assets, combining debt and equity.
- How do you interpret total liabilities & equity?
- Growth in this metric indicates the company is expanding its asset base, either through debt financing or equity issuance.
- How does total liabilities & equity compare across companies?
- Universal accounting identity; used as the denominator for calculating asset turnover and leverage ratios.